Activating somatic and germline mutations of closely related RAS genes (H, K, N) have been found in various types of cancer and in patients with developmental disorders, respectively. The involvement of the RAS signalling pathways in developmental disorders has recently emerged as one of the most important drivers in RAS research. In the present study, we investigated the biochemical and cell biological properties of two novel missense KRAS mutations (Y71H and K147E). Both mutations affect residues that are highly conserved within the RAS family. KRAS Y71H showed no clear differences to KRAS wt , except for an increased binding affinity for its major effector, the RAF1 kinase. Consistent with this finding, even though we detected similar levels of active KRAS Y71H when compared with wild-type protein, we observed an increased activation of MEK1/2, irrespective of the stimulation conditions. In contrast, KRAS K147E exhibited a tremendous increase in nucleotide dissociation generating a self-activating RAS protein that can act independently of upstream signals. As a consequence, levels of active KRAS K147E were strongly increased regardless of serum stimulation and similar to the oncogenic KRAS G12V . In spite of this, KRAS K147E downstream signalling did not reach the level triggered by oncogenic KRAS G12V , especially because KRAS K147E was downregulated by RASGAP and moreover exhibited a 2-fold lower affinity for RAF kinase. Here, our findings clearly emphasize that individual RAS mutations, despite being associated with comparable phenotypes of developmental disorders in patients, can cause remarkably diverse biochemical effects with a common outcome, namely a rather moderate gain-of-function.
INTRODUCTION
The RAS-mitogen-activated protein kinase (MAPK) pathway is a kinase cascade pathway leading to cell proliferation and differentiation and was intensively studied due to its importance in cancer development. In the past decade, a new group of genetic developmental diseases determined by germline mutations related to the RAS/MAPK pathway components were identified and intensively studied. This group of RAS-MAPK-related disorders include Noonan syndrome (NS; MIM#163950), Costello syndrome (CS; MIM#218040) and cardio-facio-cutaneous syndrome (CFCS; MIM#115150). Typical clinical features of these disorders are short stature, facial dysmorphism, skin abnormalities and cardiac defects (1, 2) .
RAS proteins (HRAS, KRAS-A, KRAS-B and NRAS) act as molecular switches and cycle between an inactive, guanosine diphosphate (GDP) bound and active, guanosine triphosphate (GTP) bound state (3) . The intrinsic functions of RAS proteins, their GDP/GTP exchange and GTP-hydrolysis are extremely slow. Guanine nucleotide exchange factors (GEFs) accelerate the exchange of bound GDP for the cellular abundant GTP (4), whereas GTPase-activating proteins (GAPs) terminate their signal transduction by stimulating the GTP-hydrolysis reaction (5) . In their GTP-bound forms, RAS proteins interact † Present address: Forschungszentrum Jülich, Institute of Complex Systems (ICS-6), Wilhelm-Johnen-Strasse, 52425 Jülich, Germany. * To whom correspondence should be addressed at: Institute of Biochemistry & Molecular Biology II, Heinrich Heine University Medical Center, Universitätsstr. 1, Düsseldorf 40225, Germany. Tel: +49 2118112384; Fax: +49 211811 2726; Email: reza.ahmadian@uni-duesseldorf.de with and regulate a spectrum of functionally diverse downstream effectors, including RAF kinases, phosphatidylinositol 3-kinase (PI3K) and RALGDS (6) .
Somatic mutations of RAS proteins are involved in 32% of human cancers with KRAS as the most frequently mutated gene (85%), followed by NRAS (12%) and HRAS (3%) (7) (8) (9) . The hot spots for cancer mutations are codons 12, 13 and 61, encoding amino acids that are fundamental for the GTP-hydrolysis reaction. In most cases, a GAP insensitivity of the mutants leads to a persistent downstream signalling. As in cases of cancer, KRAS-B is the predominantly affected isoform in RAS germline mutations associated with NS and CFCS (1,10 -17) . HRAS is the only gene associated with CS (18, 19) , and NRAS mutations were found in very rare cases of NS (20) .
Recently, we have described in detail the functional properties of a spectrum of KRAS-B and NRAS mutations related to NS (17, 20) . Overall, our studies revealed several new mechanisms by which germline KRAS mutations contribute to human disease and lead to disturbed embryonic development. Two aspects are of high importance for the understanding of RAS function(s): (i) we showed that the mild gain-of-function in the case of KRAS mutations at positions 34 and 60 is due to a mechanism counterbalancing GAP resistance by a reduced RAF1 interaction and (ii) NRAS substitution of Thr50 to isoleucine possibly leads to an impaired interaction between RAS and the plasma membrane. The latter sheds light on the role of the plasma membrane in modulating RAS signalling (20, 21) .
RAS can exert a direct control on other signalling pathways either via their multitude of effectors or indirectly via MAPK and PI3K/AKT pathways. Briefly, PI3K activation by RAS leads to the production of phosphatidylinositol 3,4,5-trisphosphate, activation of phosphoinositide-dependent kinase-1 that leads in turn to AKT-activating phosphorylation at threonine 308 (22) . Another AKT-activating event is the phosphorylation at serine 473 by mammalian/mechanistic target of rapamycin (mTOR) complex 2 (mTORC2), a protein complex which can be activated by RAS-MAPK via ERK1/2 (23) .
In the present study, we characterized biochemically two new KRAS-B mutations (termed further as KRAS) that were recently found to be associated with NS and CFCS. The patients displayed mutations at the codon p.Y71H and p.K147E, respectively. The first was found as a de novo mutation in a child with NS, whereas the second was identified in a mother and her son with a CFCS phenotype (24) . Both mutations in KRAS affect highly conserved residues within the RAS isoforms. Functional characterization using structural, biophysical and cellular biochemistry clearly shows comparable gain-of-function phenotypes of these two KRAS mutants that, however, display rather different biochemical characteristics.
RESULTS
For practical reasons (see Materials and Methods), we generated the KRAS mutations in the context of both the HRAS gene in the Escherichia coli expression system and in the KRAS gene in the eukaryotic expression system. Purified mutant RAS proteins were comprehensively characterized using advanced physical and cellular biochemistry. As controls, we used wild-type RAS (RAS wt ) and a GTPase deficient mutant (RAS G12V ).
Activation and downstream signalling of KRAS

Y71H
and KRAS
K147E
To gain insights into the regulatory cycle of the RAS mutants in cells, we transiently transfected COS-7 cells with plasmids expressing KRAS wt or the KRAS mutants G12V, Y71H and K147E. The amount of active, GTP-bound RAS in the presence of serum was determined using glutathione S-transferase (GST)-fusion proteins of the RAS-binding domain (RBD) of RAF1 (GST-RAF1-RBD) immobilized on glutathione sepharose. Interestingly, the two investigated KRAS mutants in this study exhibited quite different amounts of activated, GTP-bound states in the presence of serum. The level of activated RAS Y71H was rather comparable to RAS wt , whereas the level of activated KRAS K147E was comparable to the level of the oncogenic mutant KRAS G12V (Fig. 1A) . To uncouple KRAS activation from stimulation with growth factors present in the serum, we next performed these experiments under serum-starved conditions. Interestingly, we obtained comparable levels of the GTP-bound states as in the presence of serum, i.e. a very low level for KRAS Y71H like in the wild type and a very high level in the case of KRAS K147E comparable to KRAS G12V (Fig. 1B) . The immense accumulation of KRAS K147E in a GTP-bound active state may have various reasons, e.g. an increased GDP/ GTP exchange or an impaired intrinsic or/and GAP-stimulated GTP-hydrolysis rate. Therefore, we investigated the GAP sensitivity of these RAS mutants by repeating the GST pull-down assays under the same conditions as before, but including the catalytic GAP domain of neurofibromin (NF1-333) to the assays (25) , which was added as purified protein to the cleared cell lysates (Fig. 1B) . The results clearly indicate that both mutants, KRAS K147E and KRAS Y71H , are GAP sensitive comparable to RAS wt and in clear contrast to the GAP-insensitive KRAS G12V . The fact that the KRAS mutants exist in different states of activation due to differences in their regulatory cycle indicates that they may also cause considerable differences in their downstream signalling pathways. This was demonstrated, e.g. for CFCS-related KRAS mutants with alterations at positions Pro34 and Gly60 (17) . Therefore, we investigated the activation of the major RAS effector pathways, the RAF kinase and PI3-kinase (PI3K) signalling cascades. The phosphorylation of MEK1/2, ERK 1/2 and AKT was analyzed in COS-7 cells transiently transfected with the indicated RAS mutants and grown under serum-containing (Fig. 1C) or serum-starved (Fig. 1D) conditions. Although the expression of KRAS K147E resulted in a massive accumulation of the GTP-bound active form (Fig. 1A) and subsequent clearly elevated the activation of MEK1/2 in the presence of serum (Fig. 1C) , the activation of ERK1/2 was rather moderate in comparison to KRAS G12V (Fig. 1C) . Under serum-free conditions, we detected a hyperactivated KRAS K147E (Fig. 1B) , a moderate MEK1/2 activation and only slightly elevated pERK1/2 levels (Fig. 1D) , the latter ones clearly differing from the massive effect of expressed oncogenic KRAS
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Human Molecular Genetics, 2013, Vol. 22, No. 2 263 (Fig. 1D) . Taken together, these data indicate that KRAS K147E , regardless of its strong activation, leads to a milder gain-of-function in downstream signalling when compared with the KRAS G12V oncogenic mutation. There are two intriguing aspects coming out from KRAS Y71H mutant expression in COS-7 cells. First, KRAS Y71H expression showed, under serum induction and in comparison to the wild type, a slight increase in pMEK1/2 levels (Fig. 1C) , despite of comparable levels of the GTP-bound active form in KRAS wt and KRAS Y71H mutant, respectively (Fig. 1A) . Second, the increased pMEK1/2 level did not lead to stronger ERK1/2 activation when compared with wild-type protein (Fig. 1A) . Under serum-free conditions, we detected only a slight increase in MEK1/2 activation when compared with KRAS wt (Fig. 1D ), but this was now followed by a concomitant slight decrease in ERK1/2 activation (Fig. 1D) . Thus, the effects observed with KRAS Y71H are more subtle than expected. In addition to MEK1/2 and ERK1/2 activation, we investigated AKT-activating phosphorylation at Ser 473. We observed that KRAS Y71H leads to similar levels of phosphorylated AKT as KRAS wt , irrespective of serum conditions ( Fig. 1C and D) . KRAS K147E in the presence of serum displays similar levels of phosphorylated AKT as KRAS G12V in the presence of serum (Fig. 1C) , but in the absence of serum, the amount of phosphorylated AKT was reduced (Fig. 1D) .
Next, analysis of the downstream activities of both KRAS mutants was performed under well-defined and controlled conditions, using epidermal growth factor (EGF) stimulation in a time-dependent manner (Fig. 2) . EGF-induced activation of KRAS Y71H revealed a significantly different picture ( Fig. 2 ) when compared with our observations under serum-stimulated conditions (Fig. 1C) . Its activity toward MEK1/2 is slightly higher than KRAS wt . This rather correlates with elevated levels of pMEK1/2 in the presence of 10% serum (Fig. 1C) . However, following serum starvation and EGF treatment, the ERK1/2 phosphorylation levels by KRAS Y71H were clearly and surprisingly higher than those for KRAS wt and almost comparable to KRAS G12V ( Fig. 2 ). For the time-dependent KRAS K147E -mediated ERK activation, surprisingly EGF seems to lead to higher MEK1/2 activation when compared with KRAS G12V , but in turn similar ERK1/2 activation when compared with KRAS G12V (Fig. 2) . A different and very interesting scenario is KRAS K147E that increased significantly the level of both pAKT (Ser473) and pAKT (Thr308), comparable to KRASG12V (Fig. 1C and D) . These effects are quite consistent with the germline KRAS mutations Q22E and F156L, as demonstrated recently (17) . Hence, an important question arises as to whether KRAS mutants, identified in patients with developmental disorders, mediate exclusively activation of the RAS-MAPK pathway or whether they also differentially influence other key signalling pathways, including PI3K/AKT.
To address this issue in more detail, we studied the AKT activation via two different pathways, including ERK/mTORC2 leading to AKT phosphorylation at Ser473 and PI3K/PDK1 leading to AKT phosphorylation at Thr308 (Fig. 2) . We detected that under basal conditions (prior to EGF stimulation), KRAS Y71H caused a weaker activation of AKT when compared with the effect of KRAS K147E . On treatment with EGF for 30 s, activation of the Y71H mutant led to higher levels of pAKT when compared with KRAS wt with an earlier activation, which can be attributed to the KRAS Y71H in the absence of EGF (time point zero). The highest and most robust AKT phosphorylation at Ser473 was observed for KRAS K147E that is apparently even higher than in the presence of KRAS G12V ( Fig. 2) , despite of their similar GTP-bound levels ( Fig. 1A and B) . The difference between these two mutants is that KRAS K147E is sensitive to RASGAPs, whereas KRAS G12V is RASGAP insensitive (Fig. 1B) . The same tendency was also observed for the phosphorylation of ERK1/2 by the KRAS mutants. Contrary to the AKT phosphorylation at Ser473, no obvious difference was detectable for Thr308 phosphorylation. K147E mutant appeared to be more active than Y71H mutant (Fig. 2) . Taken together, these data support the notion that the was in this regard similar to KRAS wt . (B) Purified RASGAP, added to the cleared cell lysates, proved the GAP sensitivity for all mutants when compared with the GAP-insensitive oncogenic KRAS G12V . The same lysates were analyzed for the phosphorylation level of MEK1/2 (pMEK1/2), ERK1/2 (pERK1/2) and AKT (pAKT) under serum-induced (C) and serum-free culture conditions (D). Despite high GTP-bound levels, KRAS K147E does not lead to strong downstream signalling when compared with KRAS G12V , under the given conditions. The amounts of total RAS, MEK1/2, ERK1/2 and AKT in the cleared cell lysates and RAS wt , RAS G12V were included as controls.
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Functional characteristics of KRAS Y71H and KRAS
K147E
To analyze how the observed biochemical effects in cells are related to the molecular properties of the investigated KRAS mutants, we characterized them under in vitro conditions and analyzed the possible impact of the mutations at the structural level. Purified proteins were comprehensively studied for their intrinsic and SOS1-catalyzed nucleotide dissociation, intrinsic and neurofibromin (NF1)-stimulated GTP hydrolysis and interaction with the RAF1 effector protein. Data are summarized in Figure 3 and are shown in detail in Supplementary Material, Figure S1 . The cellular activation of RAS is generally achieved by a nucleotide exchange of bound GDP with cellular abundant GTP, which starts with the release of the bound nucleotide. Therefore, the first experiment related to RAS activation was the determination of the intrinsic nucleotide dissociation rate constants, i.e. in the absence of a GEF. We observed that RAS Y71H exhibits an exchange reaction comparable to RAS wt (Fig. 3A) . This is in agreement with the structural localization of the Tyr71 residue that is surface exposed and remote from the nucleotide binding side (Fig. 4A and B) . In addition, the in vitro exchange reaction of RAS Y71H is consistent with the levels of activated RAS Y71H in transfected COS-7 cells, especially in the absence of serum (Fig. 1B) .
In contrast, the exchange reaction of RAS K147E was strongly increased (150-fold) when compared with RAS wt and RAS Y71H (Fig. 3A) . Because Lys147 is part of the nucleotide base binding 145 SAK 147 motif ( Fig. 4A and B) , it is likely that its mutation to an inversely charged glutamate residue interferes with and weakens guanine nucleotide binding (Fig. 4D) . It is also obvious that the dramatically increased nucleotide exchange of RAS K147E is the cause for the strongly increased level of the activated GTP-bound state in transfected COS-7 cells, especially in the absence of serum (Fig. 1B) , i.e. in the absence of external stimuli and thus in the absence of upstream-activating GEFs. In summary, the 150-fold increased nucleotide exchange reaction enables the RAS K147E mutant to act as a real selfactivating mutant without the requirement of GEFs.
This finding is also in agreement with the observation that highly elevated intrinsic nucleotide exchange level of RAS K147E cannot be further activated in the presence of RASGEF SOS1 as typically observed for RAS wt under identical conditions (Fig. 3B) . Fold activation calculated from the SOS1-catalyzed reaction rates (Fig. 3B ) divided by the k obs values of the intrinsic GTP hydrolysis reactions (Fig. 3A) is 536-fold for RAS wt , 183-fold for RAS Y71H and strikingly only 1.4-fold for RAS K147E , respectively. The fact that the GEF-stimulated activation of RAS Y71H was reduced when compared with RAS wt (Fig. 3B) indicates that the substitution of Tyr71 to histidine may slightly interfere with RAS -GEF complex formation and/or GEF-mediated catalysis (Fig. 3B) .
The key properties of RAS in the active, GTP-bound state are the interaction with and subsequent activation of effectors for downstream signalling. The activated status is then terminated by an inactivating hydrolysis of GTP that is stimulated by RASGAPs. These properties are for both novel KRAS mutants only slightly altered as compared to RAS wt ( Fig. 3C  and D) , indicating that both complex formation with GAPs and effectors as well as GAP-mediated catalysis are functional. Under the conditions applied, the addition of NF1-stimulated the GTP-hydrolysis reaction for all three RAS proteins by more than three orders of magnitude. Notably, RAS Y71H exhibited even a 2-fold increased intrinsic and NF1-stimulated . COS-7 cells were stimulated with 20 ng/ml EGF and harvested at the indicated time points. Cleared cell lysates were analyzed for phosphorylated MEK1/2, ERK1/2 and AKT (Ser473 by ERK/mTORC2 and Thr308 by PI3K/PDK1), respectively (upper panels). The lower panels represent the total MEK1/2, ERK1/2 and AKT loading controls.
GTP-hydrolysis ( Fig. 3C and D) and a higher affinity for RAF1-RBD with a dissociation constant (K d ) of 26.5 nM. This corresponds to a 4-fold higher affinity of the effector as compared to that of RAS wt (K d ¼ 102 nM) (Fig. 3E ). These data indicate that the surface-exposed Tyr71 when replaced by histidine (Fig. 4A) (Fig. 3D) slightly compensates the high rates of the intrinsic nucleotide exchange (Fig. 3A) and the high levels of the GTP-bound state (Fig. 1A) and explains the lower MEK1/2 phosphorylation when compared with KRAS G12V , especially under serum-starved conditions (Fig. 1B) .
Structural characteristics of KRAS Y71H and KRAS
K147E
To understand and visualize the structural and functional effects caused by KRAS mutations, we inspected more than 50 RAS structures available in the protein database (see Supplementary Information in (17)). Overall, the location, spatial orientation and accessibility of the Tyr71 and Lys147 side chains were analyzed with respect to nucleotide binding and hydrolysis, interaction and regulation by GEFs and GAPs and the specificity of effector binding. Tyr71 is localized at the end of the switch II region of RAS proteins (Fig. 4A) . It is involved in conformational changes on GDP/GTP exchange, and its side chain, thus, faces different protein environments in the active and inactive state. However, the substitution of Tyr71 to histidine appears not to cause steric clashes with the neighboring residues. Despite the large conformational changes, Tyr71 is rather accessible and available for the interaction with regulatory proteins or effectors. The latter could be even more significant, given that an alternative conformation of Tyr71 is found in the complex structure with RAF1-RBD, where Tyr71 points outside of the protein (26) . Notably, Tyr71 and its substitute His71 are not in direct contact with the GAP or the effector proteins, but in close proximity (7 -9 Å ). Thus, the observed increase in the binding affinity for RAF1 and subsequent MEK1/2 phosphorylation cannot be attributed to direct physical changes of the RAS -RAF1 interface, but rather to the overall indirect structural effects. As highlighted in Figure 4B , these effects can be mediated through stabilization of Glu37, which is sandwiched between Tyr71 and a critical arginine in RAF1 (Arg59). Mutations of Arg59 in RAF1 or Glu37 in HRAS have been shown to impair both their complex formation and subsequent downstream signalling (27, 28) . Thus, RAF1 binding to the switch I region appears to sense also the switch II conformation via indirect interaction with Tyr71 (Fig. 4B) . Thus, we hypothesize that KRAS Y71H undergoes a stronger binding to the RAF1-RBD because His71 may provide an additional hydrogen bond to contact Glu37 when compared with Tyr71. A similar scenario could be applied for the KRAS Y71H interaction with the RASGAP as the GAP-stimulated reaction was 2-fold increased. Glu37 is also a critical RASGAP binding residue (29) .
The residue Lys147 is an integral part of the conserved 145 SAK 147 motif that is important for guanine base binding ( Fig. 4A and C) . Lys147 does not change its position on the nucleotide-dependent conformational switch of RAS. It is located in close vicinity, but does not directly bind to the guanine base of the bound nucleotide. Lys147 exhibits two major interactions and, thus, contributes indirectly to highaffinity guanine nucleotide binding (Fig. 4C) . It makes 
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Human Molecular Genetics, 2013, Vol. 22, No. 2 strong aliphatic interaction with Phe28 and, thus, orientates this residue that directly contacts the guanine base. The amino group of Lys147 is in contact with the conserved Asp119 via two water molecules stabilizing its interaction with the guanine base by two hydrogen bonds (Fig. 4C) . Mutations of both residues have been shown to dramatically change nucleotide binding properties of HRAS. HRAS F28L exhibits an increased nucleotide dissociation rate (30) . HRAS D119N revealed a shift in its specificity from guanosine to xanthosine nucleotides (31) and acts as a strong dominant-negative mutant in cells (32) .
Lys147 is a conserved amino acid within the RAS family proteins suggesting that its interactions are of structural and functional importance. Disturbing these interactions by the substitution of Lys147 to an acidic glutamic acid has, thus, a massive impact on the affinity of KRAS for guanine nucleotides ( Fig. 2A) . K147E mutation obviously causes three cumulative effects (Fig. 4D) . First, Glu147 apparently stabilizes Phe28 for guanine base binding as effectively as Lys147 does. Second, the acidic side chain of Glu147 causes an electrostatic repulsion with the Asp119 and consequently a strong increase in the nucleotide dissociation rate of this mutant. Third, Glu147 partially replaces the loss of Asp119 function by directly contacting the guanine base itself. We think that without the latter protective effect, HRAS K147E may behave as a strong dominant-negative mutant that is described to have a high affinity for the RASGEFs and to inhibit RAS activation (32) .
DISCUSSION
One of the most exciting recent developments in human genetics has been the identification of heterozygous germline mutations in key components of the highly conserved RAS-MAPK pathway as the cause of developmental disorders (33 -35 ). An overall increase in activation of the RAS-MAPK pathway is thought to be the common pathophysiologic denominator for clinically overlapping syndromes, including NS, CFCS and CS (2) . A large number of germline RAS mutations have been identified in the last 5 years. KRAS and NRAS mutations are causally related with NS (1, 12, 16, 17, 20, 36) , some KRAS mutations with CFCS (12, 17, 37) and HRAS mutations with CS (18, 19, (38) (39) (40) . Functional effects caused by the majority of these mutations, which are markedly different from RAS mutations found in human cancer, are diverse and can be grouped into different classes according to their pattern of functional alterations (17) . The two KRAS variants characterized in this study clearly demonstrate how different (non-overlapping) and diverse the structural and functional effects can be to cause a mild, non-lethal gain-of-function phenotype (24) . To visualize these effects, we analyzed the structure -property -function relationship of these new variants in vivo, in vitro and in silico, in direct comparison to KRAS wt and KRAS G12V . RAS Y71H did not show any obvious differences to RAS wt regarding its activation, but revealed a lower basal GTP level in the absence of stimuli, like EGF. Moreover, a slight but significant increase in RAF1 effector binding and consequently increased activation of MEK1/2 and ERK1/2 kinases were observed. These effects are most obvious in the time course of EGF stimulation (Fig. 2) . Substitution of lysine at position 147 by glutamic acid very likely disturbs the guanine base coordination (Fig. 4D) and thus weakens the overall nucleotide binding. This leads due to the abundant cellular GTP to elevated active KRAS K147E mutant, irrespective of stimulation conditions and GEF activity. In contrast to oncogenic KRAS G12V , where the activated state stays persistent due to an impaired GAP-catalyzed GTP hydrolysis, the RAS K147E mutant can be still inactivated by the GAP function as efficiently as activated KRAS wt . Moreover, and characteristically for a NS and CFCS variant, the elevated signal of active KRAS K147E is not transmitted as efficiently through the MAPK pathway as seen for the strong KRAS
G12V
. This can be partially caused by a lower binding affinity for the downstream effector, i.e. RAF1. Intriguingly enough, KRAS Y71H , despite stronger affinity to RAF and stronger activation of MEK1/2, did not lead to a similar increase in ERK1/2 activation when compared with the wild type. It is not surprising that MEK1/2 does not show strong activation because even in cancer cell lines with endogenous oncogenic RAS isoforms, the activation of downstream signalling was not evident, as observed in pancreatic cell lines, leukemia cells and mouse embryonic fibroblasts from a mouse model expressing oncogenic KRAS (41) (42) (43) (44) .
Taking into account the overall properties of KRAS mutants from the present study, we add them into the classification of KRAS mutants leading to developmental disorders (17) . Because the properties of KRAS Y71H are similar to the wild type, with the exception of the higher effector affinity, it belongs to class A of mutations. KRAS K147E based on its fast intrinsic dissociation (faster than the previously studied KRAS F156L ), abrogated SOS1-catalyzed nucleotide exchange and slight reduction in effector binding can be placed in class D of mutations.
Another interesting aspect to be mentioned is the posttranslational modification of KRAS at Lys147 and probably also at Tyr71. Recent studies have shown that RAS proteins are ubiquitinated at the Lys 147, which leads to increased RAS activation by GEF proteins (45) . A small fraction of the total RAS is ubiquitinated, which seems to represent an important amount of the PI3K-or RAF-bound active RAS (45) . Therefore, Lys147 substitution to glutamate will possibly hinder ubiquitination and, in spite of the considerable amount of active KRAS K147E accumulated in the cells, the number of RAS molecules bound to their effector proteins is reduced. Moreover, KRAS G12V/K147L showed that in the absence of ubiquitination, the tumors are smaller than the control KRAS G12V (45) . This may be another explanation why KRAS K147E despite immense accumulation in its active state exhibits only mild gain-of-function effects. Interestingly, Ser71, an equivalent residue in RAC1, has been shown to be a target of serine/threonine kinases, which if phosphorylated diminishes microbial pathogenesis by blocking RAC1 glucosylation by bacterial toxins (46) . Taking the high structural identity of RAS and RAC1 into account, it is tempting to speculate that Tyr71 phosphorylation of KRAS by tyrosine kinases may likewise contribute negatively to RAS signalling, a scenario that would be perturbed in the case of KRAS Y71H . It seems that RAS mutations leading to developmental disorders might be the sum of all effects of RAS effector proteins. The phenotype/pathology observed in patients can be correlated with the biological functions derived from disturbed signalling of the wide variety of RAS effector proteins. In addition to the complexity brought by the wide variety of RAS effectors, not only the RAS/RAF/MEK/ERK axis may well be affected by RAS mutations. Using either MEK 1/2 inhibitors or siRNA against MEK1/2, one may monitor both RAF activity on other substrates and the ERK1/2 activation by other pathways. For example, eukaryotic translation elongation factor 1A, apoptosis-linked gene-2, Bcl-2-associated death promoter and their phosphorylation by RAF appear to have prosurvival functions (47 -49) and might influence embryonic development. In addition, using MEK inhibitors or MEK siRNA, one can shed light as well in the ERK1/2 activation from p21-activated kinase 1 (PAK1), a mechanism important in lamellopodial dynamics (50) . Posttranslational modification, including phosphorylation and ubiquitination, adds an additional degree in modulating RAS signalling that needs further attention.
A remarkable issue that should be mentioned at this point is the substitution of the highly conserved, positively charged lysine 147 for a negatively charged glutamic acid in the case of KRAS K147E . Such substitutions often cause drastic changes in the attractive and/or repulsive interactions between adjacent amino acid residues. Interestingly, K147E mutation in KRAS is not as drastic as it seemed at first view. A comparison of Figure 4C and D shows that the interaction with Asp119 is basically affected. Such an effect is sufficient to cause a 150-fold increase in the GDP dissociation from KRAS K147E (Fig. 3A) . However, all other contacts of the Lys147 side chain with both the nucleotide and particularly Phe28 are preserved by the Glu147 side chain. We hypothesize that a germline mutation causing a substitution of Lys147 with a smaller side chain such as alanine or glycine is highly likely lethal. Such a KRAS protein may function as a strong dominant-negative mutant and inhibit RAS signalling in cell during development. We conclude that most mutations associated with developmental disorders, including KRAS K147E , are permissive mutations and are, thus, tolerated in the germline. Therefore, it is of major importance to look attentively at substituting amino acid, too.
MATERIALS AND METHODS
Plasmids and proteins
All constructs were produced and purified as described (19, 20, 25, 51) . Fluorescent nucleotide-loaded RAS proteins were prepared as described previously (52) .
Kinetics of nucleotide dissociation and GEF-catalyzed nucleotide dissociation
Intrinsic dissociation of mant-GDP was quantified using a LS 50 B fluorescence spectrophotometer (Perkin Elmer) (19, 53) , and GEF-catalyzed mant-GDP dissociation from RAS proteins was studied using an Hightech stopped-flow apparatus as described (19, 20, 52, 54) . Observed rate constants (k obs ) were obtained by single exponential fitting of the data.
Intrinsic and GAP-stimulated GTP hydrolysis
Intrinsic and GAP-stimulated GTP hydrolysis of the RAS proteins was performed as described (25, 52, 54) .
RAS/RAF1-RBD binding measurements
Interaction of RAS with RAF1-RBD was determined by isothermal titration calorimetry (ITC) using a VP-ITC-Isothermal Titration Calorimeter (Microcal, GE Healthcare) in 30 mM Tris-HCl, pH 7.6, 50 mM NaCl, 5 mM MgCl 2 at 258C. GppNHp-loaded RAS proteins were filled into the sample cell and titrated with RAF-RBD. General instrument settings were as follows: 258C, initiation delay 240 s, spacing 240 s, 11-13 mCal/sec reference power, 5 -6 ml injection volume.
268
Human Molecular Genetics, 2013, Vol. 22, No. 2
Cell-based assays
All cell-based experiments were performed as described (17, 20) . The EGF experiments were performed at a final concentration of 20 ng EFG (Sigma) per milliliter of culture medium. Antibodies for immunoblotting against RAS were obtained from Millipore TM . Antibodies against MEK1/2, ERK1/2, AKT, phospho-MEK1/2 (Ser217/221), phospho-ERK1/2 (Thr202/Tyr204) and phospho-AKT (Ser473 or Thr308) were from Cell Signalling Technology.
Structural methods
Because no KRAS
wt structure is available to date, the structures of HRAS were used in our study. The G-domains of HRAS and KRAS share 97% identity and are generally accepted to be structurally very similar, if not identical (25) . The differences between the active and inactive state of RAS were analyzed by comparison of the GDP-bound (55) Protein Data Bank code [4Q21] and GTP-bound (56) [1CTQ] HRAS structure, respectively. These structures were selected because they represent wild-type RAS (RAS 
